Background
==========

Allergic conjunctivitis (AC) commonly manifests as itchy, watering or red eyes, which comprise the symptoms of the total ocular symptom scores (TOSS) \[[@B1]-[@B3]\].

The incidence of AC in developed countries is 20% \[[@B4]-[@B6]\] with a high co-morbidity of allergic rhinitis (AR) \[[@B5],[@B6]\]. Recognition of AC is unreported even in patients with recognised AR \[[@B6],[@B7]\]. Under-recognition of AR is common, with the proportion of undiagnosed AR patients ranging from 25--60% \[[@B8]\].

Clinically, it is apparent that AC patients have heightened sensitivity, tending to blink and squint more, contributing to frontal tension headaches. Rubbing of eyelids can contribute to dermatitis, with patients focusing more on the dermatitis than conjunctival symptoms.

Olopatadine hydrochloride 0.1% was selected for its efficacy in AC, providing negligible side effect profile and rapid onset of action, evident from five minutes post administration \[[@B9]-[@B12]\].

Objective
---------

Identify the incidence of AC in patients with AR.

Methods
=======

One hundred and eighty seven consecutive patients -- paediatrics and adults, during pollen season, with Allergist diagnosed AR attending an outpatient clinic in Southport, on the Gold Coast, were directly questioned if they have AC, clarified by using standard screening questions of red, itchy and watery eyes and quantified by TOSS. Patients were asked about indirect symptoms that may be attributable to AC: eyelid dermatitis, frequent blinking, eye sensitivity and frontal headache. Patients were given a drop of Olopatadine in each eye to help identify "silent" disease.

Patients were prospectively diagnosed with allergic rhinitis based on clinical history, examination and concurrent skin prick testing by an allergy specialist. Patients were instructed not to take antihistamines for at least 48 hours prior to assessment.

Twenty controls without a clinical history of AR or AC were also treated with olopatadine drops to determine if there was a non-specific lubricating effect of olopatadine hydrochloride.

We did not note history of lasik surgery or pterygia in any of our patients, nor were any of our participants wearing contacts at the time of olopatadine administration.

Ethics approval was obtained from Griffith University Human Research Ethics Committee.

This trial was registered with Australia New Zealand Clinical Trials Registry (ANZCTR).

Data was analyzed using Microsoft Excel data-base software (Microsoft Corp., Redlands, CA) using a paired t-test for pre and post TOSS with Olopatadine challenge. A Pearson correlation coefficient was used to compare relationship between TOSS positivity and presence of additional symptoms and the presence of symptoms and response to a therapeutic challenge with olopatadine

Results
=======

Fifty three percent of patients identified themselves as having AC on direct questioning and enquiring about specific TOSS symptoms. Additional possible symptoms attributable to AC were squint 51%, blinking 52%, frontal headache 60% and eyelid dermatitis 45%.

Olopatadine reduced TOSS scores within 5 minutes of treatment (1.34 +/− 1.66 vs 0.486 +/− 0.83. p \< 0.01). 146 (78.1%) subjects noted improvement verses 41 (21.9%) noting no change in ocular symptoms. Based on a negative history of AC and baseline TOSS of 0, therapeutic challenge of Olopatadine identified 77 (41.2%) silent sufferers of AC.

No effect on TOSS was observed in control patients treated with olopatadine.

One hundred and sixty six (88.8%) AC subjects were identified through TOSS symptoms. Plausible indirect AC symptoms detected 158 (84.5%) subjects. However, combining standard TOSS and additional questions detected 177 (94.7%) AC subjects. Presence of additional ocular symptoms correlated both with TOSS responses and beneficial effect of a therapeutic challenge with Olopatadine (r = 0.60 , P \< 0.05).

Discussion
==========

AC was identified in 53.5% of patients with AR using direct questioning in relation to history of AC. This is comparable with other studies \[[@B6],[@B7],[@B13]-[@B18]\]. Specific questioning regarding indirect symptoms increased the incidence of AC in patients with AR to 94.7%. Olopatadine therapeutic challenge was performed in 20 healthy, non-atopic controls to ensure there was no non-specific lubricating effect of the eye drop.

As this was a therapeutic challenge, a lubricant could have improved symptoms and it would most likely help patients with allergic conjunctivitis. There was no improvement in controls that were given this lubricant effect and hence TOSS improvement can be attributed to olopatadine, not to non-specific lubricating effect.

The co-existence of AC is well recognised in patients with AR \[[@B6],[@B7],[@B13]-[@B18]\] although co-reporting frequency may be as low as 40%. Under-recognition of allergic conjunctivitis may be due to patients and physicians paying more attention to allergic comorbidities such as AR or rhinitis or the under-appreciation of the variability of eye symptoms in patients with AC \[[@B6],[@B19]-[@B21]\].

Our study confirms patients have an under-appreciation of symptoms, even when prompted with specific questions, and the value of a therapeutic challenge. Our data suggests approximately 40% of AR patients felt their symptoms represented as normal. This is significant because the presence and lack of treatment of AC contributes negatively to their quality of life \[[@B22]\].

Limitations of this study include; it was an open clinical audit and direct survey questions were used. Questions of children were occasionally influenced by their parent's answers or prompting. Headache is a symptom associated with AR \[[@B3]\] and may not localise towards ocular symptoms. However we did find an association with a history of headache and response to a therapeutic challenge.

Conclusion
==========

In conclusion, the standard AC screening questions identified just over half of the patients with AC. As suggested by others, the absence of a history does not negate the value of examining the conjunctiva. Additionally we suggest that symptoms of blinking, squinting, eyelid dermatitis and frontal headache and use of olopatadine hydrochloride eye drops can help identify patients with "silent" symptoms.
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